Phase I study of recombinant human tumor necrosis factor (original) (raw)
References
Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YCE, Mathison J, Cerami A (1985a) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316: 552–554 Google Scholar
Beutler B, Millsark IW, Cerami AC (1985b) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–871 Google Scholar
Blick MB, Sherwin SA, Rosenblum MG, Gutterman JU (1986) A phase I trial of recombinant tumor necrosis factor (rTNF) in cancer patients. Proc Soc Clin Oncol 5: 14 Google Scholar
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666–3670 Google Scholar
Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Kempin S, Welt S, Sherwin S, Old LJ, Oettgen HF (1986) Phase I study of recombinant tumor necrosis factor (rTNF). Proc Am Soc Clin Oncol 5: 231 Google Scholar
Conners JM, Silver HKB (1984) Phase I study of weekly high-dose human lymphoblastoid interferon. Cancer Treat Rep 68: 1092–1096 Google Scholar
Degliantoni G, Murphy M, Kobayashi M, Francis MK, Perussia B, Trichieri G (1985) Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. J Exp Med 162: 1512–1530 Google Scholar
Gutterman JU, Seymour F, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dzienwanowski Z (1982) Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96: 549–556 Google Scholar
Hayashi H, Kiyota T, Sakamoto H, Seto M (1986a) An enzyme-linked immunosorbent assay for recombinant human tumor necrosis factor using monoclonal antibody. In: Ishigami J (ed) Recent advance in chemotherapy. Anticancer section 2. University of Tokyo Press, Tokyo, pp 820–821 Google Scholar
Hayashi H, Oishi J, Hori K, Maeda N (1986b) Biological activities of recombinant human tumor necrosis factor. In: Ishigami J (ed) Recent advance in chemotherapy. Anticancer section 2. University of Tokyo Press, Tokyo, pp 818–819 Google Scholar
Khan A, Pardue A, Aleman C, Dickson J, Pichyangkul S, Hill JM, Hilario R, Hill NO (1986) Phase I clinical trial with recombinant tumor necrosis factor (TNF). Proc Am Soc Clin Oncol 5: 226 Google Scholar
Matthews N, Watkins JF (1978) Tumor-necrosis factor from the rabbit: I. Mode of action, specificity and physiochemical properties. Br J Cancer 38: 302–309 Google Scholar
Murase T, Hotta T, Saito H, Ohno R (1987) Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood 69: 467–472 Google Scholar
Ohno R, Kimura K, Amaki I, Imamura Y, Masaoka T, Miyazaki T, Yoshida Y, Miura Y, Maekawa T, Oguro M, Takaku F, Miwa S, Osamura S, Mizoguchi H, Nomura T, Shimoyama M, Sakai Y, Ohta K, Hattori K, Uchino H, Yamada K (1985) Treatment of multiple myeloma with recombinant human leukocyte A interferon. Cancer Treat Rep 69: 1433–1436 Google Scholar
Old LJ (1985) Tumor necrosis factor. Science 230: 630–632 Google Scholar
Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312: 724–729 Google Scholar
Playfair JHL, de Souza JB, Taverne J (1982) Endotoxin-induced “tumor-necrosis serum” kills a subpopulation of normal lymphocytes in vitro. Clin Exp Immunol 47: 753–755 Google Scholar
Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU (1986) Clinical toxicity of interferons in cancer patients. J Clin Oncol 4: 234–243 Google Scholar
Rohatiner AZS, Balkwill FR, Griffin DB, Malpas JS, Lister TA (1982) A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol 9: 97–102 Google Scholar
Rosenberg SA, Lotze MT, Muul L, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shironi E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observation on the systemic administration on autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492 Google Scholar
Ruff MR, Gifford GE (1981) Rabbit tumor necrosis factor: mechanism of action. Infect Immun 31: 380–385 Google Scholar
Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB (1985) Cloning and expression in_Escherichia coli_ of the gene for human tumor necrosis factor. Nature 313: 803–806 Google Scholar
Strander H, Cantell K, Carlstrom G, Jakobsson PA (1973) Clinical and laboratory investigations on man: systemic administration of potent interferon to man. J Natl Cancer Inst 51: 733–742 Google Scholar
Sugarman BJ, Aggarwall BB, Hass PE, Figari PE, Palladino MA Jr, Shepard HM (1985) Recombinant human tumor necrosis factor: Effect of proliferation of normal and transformed cells in vitro. Science 230: 943–945 Google Scholar
Taguchi T, Shiratori T, Kodama M, Takahashi T, Okajima K, Mori T, Mogami H, Ono K, Yoshikawa K, Sakai K, Terasawa T, Masaoka T, Kotake T, Tsubura E, Yasutomi M, Shimoyama T, Okamoto E, Yasutake K, Irie K, Ikeda S, Akahoshi Y, Mori S, Matsunaka M (1986a) Clinical studies of recombinant human tumor necrosis factor (rHu-TNF: PT-050). Abstracts of the 14th International Cancer Congress, Budapest 1986, vol 3, p 1159 Google Scholar
Taguchi T, Urushizaki I, Wakui A, Koyama Y, Saito T, Niijima T, Takakura K, Izuo M, Ikeda S, Kondo T, Kimura K, Ohta K, Akaboshi Y, Ogura T, and Hattori T (1986b) Phase I trial of recombinant interleukin-2 (TGP-3): In: Ishigami J (ed) Recent advance in chemotherapy. Anticancer section 2. University of Tokyo Press, Tokyo, pp 804–805 Google Scholar
Tanneberger ST, Milleck J, Müller U, Gürtler R (1986) Preliminary results with the application of recombinant human tumor necrosis factor (rH-TNF) in cancer patients. Abstracts of the 14th International Cancer Congress, Budapest 1986, vol 3, p 1159 Google Scholar
Umeda T, Hara T, Niijima T (1983) Cytotoxic effect of tumor necrosis factor on human lymphocytes and specific binding of the factor to the target cells. Cell Mol Biol 29: 349–352 Google Scholar
Vadhan-Raj S, Al-Katib A, Bhalla R, Pelus L, Nathan CF, Sherwin SA, Oettgen HF, Krown SE (1986) Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 4: 137–146 Google Scholar
Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ (1983) Human tumor necrosis factor produced by human B-cell lines: synergestic cytotoxic interaction with interferon. Proc Natl Acad Sci USA 80: 5397–5401 Google Scholar
Zubrod CG, Sneiderman M, Frei E III, Bridley C, Gold L, Schneider B, Oviedo R, Gorman J, Jones R Jr, Johnson U, Colsky J, Chalmers T, Ferguson B, Dedrick M, Holland J, Selawry Q, Regelson W, Lasagna L, Owens AH Jr (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphamide. J Chron Dis 11: 7–33 Google Scholar